Heparin-induced thrombocytopenia: A ten-year retrospective

Annual Review of Medicine

Volumn 50, Issue , 1999, Pages 129-147

  Warkentin, Theodore E ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antibody; Danaparoid; Hirudin; Thrombin; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; DANAPAROID; FC RECEPTOR; HEPARIN; IMMUNOGLOBULIN G ANTIBODY; LEPIRUDIN; PROCOAGULANT; THROMBIN; THROMBOCYTE FACTOR 4; THROMBOCYTE RECEPTOR; WARFARIN;

DEEP VEIN THROMBOSIS; DRUG USE; ENDOTHELIUM; GANGRENE; HUMAN; LABORATORY DIAGNOSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; ANTITHROMBIN III; CHONDROITIN SULFATES; DERMATAN SULFATE; DRUG COMBINATIONS; FIBRINOLYTIC AGENTS; GANGRENE; HEPARIN; HEPARINOIDS; HEPARITIN SULFATE; HIRUDIN THERAPY; HIRUDINS; HUMANS; IMMUNOGLOBULIN G; LEG; PLATELET ACTIVATION; PLATELET FACTOR 4; PROTEIN C DEFICIENCY; RECEPTORS, IGG; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SYNDROME; THROMBIN; THROMBOCYTOPENIA; VENOUS THROMBOSIS; WARFARIN;

EID: 0032977821     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.50.1.129     Document Type: Review

References (59)

1. 1. Warkentin TE, Kelton JG. 1989. Heparin-induced thrombocytopenia. Anna. Rev. Med. 40:31-44
2. 2. Warkentin TE, Levine MN, Hirsh J, et al. 1995. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332: 1330-35
3. 3. Warkentin TE, Kelton JG. 1996. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med. 101:502-7
4. 4. Nand S, Wong W, Yuen B, et al. 1997. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am. J. Hematol. 56:12-16
5. 5. Warkentin TE, Elavathil LJ, Hayward CPM, et al. 1997. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. 127:804-12
6. 6. Warkentin TE. 1996. Heparin-induced thrombocytopenia: IgG-mediated platelet activation, platelet microparticle generation, and altered procoagulant/anticoagulant balance in the pathogenesis of thrombosis and venous limb gangrene complicating heparin-induced thrombocytopenia. Transfus. Med. Rev. 10:249-58
7. 7. Amiral J, Bridey F, Dreyfus M, et al. 1992. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb. Haemost. 68:95-96 (Letter)
8. 8. Warkentin TE, Hayward CPM, Boshkov LK, et al. 1994. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84: 3691-99
9. 9. Warkentin TE. 1998. Limitations of conventional treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 35(Suppl. 4): 17-25
10. 10. Warkentin TE, Chong BH, Greinacher A. 1998. Heparin-induced thrombocytopenia: towards consensus. Thromb. Haemost. 79:1-7
11. 11. Chong BH, Ismail BH. 1989. The mechanism of heparin-induced platelet aggregation. Eur. J. Haematol. 43:245-51
12. 12. Warkentin TE, Kelton JG. 1994. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases, ed. H Bounameaux, pp. 75-127. New York: Dekker
13. 131) gene in patients with heparin-induced thrombocytopenia. J. Lab. Clin. Med. 130:278-84
14. 14. Kelton JG, Sheridan D, Santos A, et al. 1988. Heparin-induced thrombocytopenia: laboratory studies. Blood 72: 925-30
15. 15. Warkentin TE, Kelton JG. 1999. Thrombocytopenia due to platelet destruction and hypersplenism. In Hematology. Basic Principles and Practice, ed. R Hoffman, EJ Benz Jr, SJ Shattil, et al. New York: Churchill Livingstone. 3rd ed. In press
16. 16. Greinacher A, Michels I, Mueller-Eckhardt C. 1992. Heparin-associated thrombocytopenia: the antibody is not heparin specific. Thromb. Haemost. 67: 545-49
17. 17. Kelton JG, Smith JW, Warkentin TE, et al. 1994. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 83:3232-39
18. 18. Visentin GP, Ford SE, Scott JP, et al. 1994. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93:81-88
19. 19. Collins JL, Aster RH, Moghaddam M, et al. 1997. Diagnostic testing for heparin-induced thrombocytopenia (HIT): an enhanced platelet factor 4 complex enzyme linked immunosorbent assay (PF4 ELISA). Blood 90(Suppl. 1):461a (Abstr.)
20. 20. Greinacher A, Michels I, Schäfer M, et al. 1992. Heparin-associated thrombocytopenia in a patient treated with polysulphated chondroitin sulphate: evidence for immunological crossreactivity between heparin and polysulphated glycosaminoglycan. Br. J. Haematol. 81:252-54
21. 21. Tardy-Poncet B, Tardy B, Grelac F, et al. 1994. Pentosan polysulfate-induced thrombocytopenia and thrombosis. Am. J. Hematol. 45:252-57
22. 22. Rollins BJ. 1997. Chemokines. Blood 90: 909-28
23. 23. Amiral J, Marfaing-Koka A, Wolf M, et al. 1996. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 88: 410-16
24. 24. Warkentin TE. 1998. Clinical presentation of heparin-induced thrombocytopenia. Semin. Hematol. 35 (Suppl. 4): 9-16
25. 25. Chong BH, Grace CS, Rozenberg MC. 1981. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br. J. Haematol. 49:531-40
26. 26. Warkentin TE, Sheppard JI, Santos AV. 1994. Generation of platelet-derived microparticles and procoagulant activity by IgG platelet agonists: comparison with standard platelet agonists. Blood 84 (Suppl. 1):528a (Abstr.)
27. 27. Cines DB, Tomaski A, Tannenbaum S. 1987. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N. Engl. J. Med. 316:581-89
28. 28. Visentin GP, Moghaddam M, Aster RH. 1997. Antibodies associated with heparin-induced thrombocytopenia/thrombosis (HITP) recognize sites on platelet factor 4 (PF4) induced by the binding of linear polyanionic compounds. Thromb. Haemost. 77(Suppl.):362 (Abstr.)
29. 29. Greinacher A, Alban S, Dummel V, et al. 1995. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb. Haemost. 74:886-92
30. 30. Horsewood P, Warkentin TE, Hayward CPM, et al. 1996. The epitope specificity of heparin-induced thrombocytopenia. Br. J. Haematol. 95:161-67
31. 31. Visentin GP, Malik M, Cyganiak KA, et al. 1996. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin:platelet factor 4 complexes. J. Lab. Clin. Med. 128:376-83
32. 32. Kappers-Klunne MC, Boon DMS, Hop WCJ, et al. 1997. Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular disease. Br. J. Haematol. 96:442-46
33. 33. Warkentin TE, Hirte HW, Anderson DR, et al. 1994. Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am. J. Med. 97:489-91
34. 34. Ling E, Warkentin TE. 1998. Intraoperative heparin flushes and subsequent acute heparin-induced thrombocytopenia. Anesthesiology 89: In press
35. 35. Warkentin TE, Kelton JG. 1998. Timing of heparin-induced thrombocytopenia (HIT) in relation to previous heparin use: absence of an anamnestic immune response, and implications for repeat heparin use in patients with a history of HIT. Blood 92(Suppl. 1):182a
36. 36. Warkentin TE. 1996. Heparin-induced skin lesions. Br. J. Haematol 92:494-97
37. 37. Warkentin TE. 1997. Heparin-induced thrombocytopenia, heparin-induced skin lesions, and arterial thrombosis. Thromb. Haemost. 77(Suppl.):562 (Abstr.)
38. 38. Popov D, Zarrabi H, Foda H, et al. 1997. Pseudopulmonary embolism: acute respiratory distress in the syndrome of heparin-induced thrombocytopenia. Am. J. Kidney Dis. 29:449-52
39. 39. Sheridan D, Carter C, Kelton JG. 1986. A diagnostic test for heparin-induced thrombocytopenia. Blood 67:27-30
40. 40. Warkentin TE, Hayward CPM, Smith CA, et al. 1992. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J. Lab. Clin. Med. 120:371-79
41. 41. Greinacher A, Michels I, Liebenhoff U, et al. 1993. Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides. Br. J. Haematol 84:711-16
42. 42. Greinacher A, Amiral J, Dummel V, et al. 1994. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzymelinked immunosorbent assay. Transfusion 34:381-85
43. 43. Chong BH, Burgess J, Ismail F. 1993. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb. Haemost. 69:344-50
44. 44. Greinacher A, Michels I, Kiefel V, et al. 1991. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb. Haemost. 66:734-36
45. 45. Lee DH, Warkentin TE, Denomme GA, et al. 1996. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br. J. Haematol. 95:724-31
46. 46. Tomer A. 1997. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br. J. Haematol. 98:648-56
47. 47. Newman PM, Swanson RL, Chong BH. 1998. Heparin-induced thrombocytopenia: IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low molecular weight heparin and heparinoid. Thromb. Haemost. 80: 292-97
48. 48. Chong BH. 1996. Low molecular weight heparinoid and heparin-induced thrombocytopenia. Aust. NZ J. Med. 26:331 (Abstr.)
49. 49. Magnani HN. 1997. Orgaran (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 8: 74-81
50. 50. Warkentin TE. 1996. Danaparoid (Orgaran ) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation, and evaluation of the clinical significance of in vitro cross-reactivity (XR) of danaparoid for HIT-IgG. Blood 88(Suppl. 1): 626a (Abstr.)
51. 51. Markwardt F. 1992. Hirudin: the promising antithrombotic. Cardiovasc. Drug Rev. 10:211-32
52. 52. Greinacher A, Völpel H, Pötzsch B. 1996. Recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Blood 88(Suppl. 1): 281a (Abstr.)
53. 53. Eichler P, Greinacher A. 1996. Antihirudin antibodies induced by recombinant hirudin in the treatment of patients with heparin-induced thrombocytopenia (HIT). Ann. Hematol. 72(Suppl.):A4 (Abstr.)
54. 54. Lewis BE, Walenga JM, Wallis DE. 1997. Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. Semin. Thromb. Hemost. 23: 197-202
55. 55. Weinmann EE, Carpenter JP. 1996. Intraoperative urokinase as an alternative to heparin for patients with suspected heparin-induced thrombocytopenia requiring arterial reconstruction: report of a case and review of the literature. J. Cardiovasc. Surg. 37:463-65
56. 56. Kappa JR, Fisher CA, Todd B, et al. 1990. Intraoperative management of patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg. 49:714-23
57. 57. Polgár J, Eichler P, Greinacher A, et al. 1998. Adenosine diphosphate (ADP) and ADP receptor play a major role in platelet activation/aggregation induced by serum from heparin-induced thrombocytopenia patients. Blood 91:549-54
58. 58. Demers C, Ginsberg JS, Brill-Edwards P, et al. 1991. Rapid anticoagulation using ancrod for heparin-induced thrombocytopenia. Blood 78: 2194-97
59. 59. Warkentin TE. 1997. Heparin-induced thrombocytopenia: pathogenesis, frequency, avoidance, and management. Drug Saf. 17:325-41